Earlier Diagnosis the Myocardial Infarction of Older Patients by Troponin Test
DOI:
https://doi.org/10.59675/M215Keywords:
diagnosis, myocardial, infarction, older, patients, troponin, testAbstract
Background: Finding elevations or decreases in cardiac troponin (cTn) is crucial for the early diagnosis of myocardial infarction (MI). Myocardial necrosis is indicated by cardiac troponins. They are the favored due to their strong cardiac selectivity. Biomarker to detect instances of MI. Techniques: Seventy older people between the ages of 55 and 75 were involved in a prospective comparison study that took place between January 2021 and December 2023. They were split up into two groups: the first group consisted of 70 patients, while the second group contained 50 healthy people as a control group. Results: Sensitive troponin I testing significantly improved the diagnosis of myocardial infarction in women (from 12% to 23%; P < 0.001) but had little effect on males (from 21% to 23%; P = 0.002). P < 0.05 was less likely in women than in men for both coronary artery revascularization and cardiologist referral. Women with unexplained increases in troponin concentration (16–48 ng/L) and those with myocardial infarction (≥55 ng/L) had higher rates of death or re-infarction at 24 months (26%, 28%, and 6%, respectively; P < 0.001), as compared to women without myocardial infarction (≤18 ng/L). Conclusion: elevated sensitivity a sex-specific diagnostic beginning for the troponin assay might binary the identification of myocardial infarction in women and recognize those who are most vulnerable to reinfarction and demise. Whether applying sex-specific analytic thresholds will enhance results and address issues, even though they don't really affect males disparities in how women are treated who may have care for acute coronary syndrome must be given immediately.
References
Chaulin AM, Duplyakov DV. Environmental factors and cardiovascular diseases. Hygiene and Sanitation. 2021;100(3):223-228. (In Russ). DOI: https://doi.org/10.47470/0016-9900-2021-100-3-223-228
Chaulin AM, Sergeev AK. The role of fine particles (PM 2.5) in the genesis of atherosclerosis and myocardial damage: emphasis on clinical and epidemiological data, and pathophysiological mechanisms. Cardiol Res. 2022;13(5):268-282 DOI: https://doi.org/10.14740/cr1366
Collaborators GBDCoD. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1736-1788 DOI: https://doi.org/10.1016/S0140-6736(18)32203-7
Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. J Am Coll Cardiol 2012;60:1581–98 DOI: https://doi.org/10.1016/j.gheart.2012.08.001
Collinson PO, van Dieijen-Visser MP, Pulkki K, Hammerer-Lercher A, Suvisaari J, Ravkilde J, et al. Evidence-based laboratory medicine: how well do laboratories follow recommendations and guidelines? The Cardiac Marker Guideline Uptake in Europe (CARMAGUE) study. Clin Chem 2012;58:305–6. DOI: https://doi.org/10.1373/clinchem.2011.171439
Keller T, Zeller T, Peetz D, Tzikas S, Roth A, Czyz E, et al. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med 2009;361:868–77. DOI: https://doi.org/10.1056/NEJMoa0903515
Mills NL, Churchhouse AM, Lee KK, et al. Implementation of a sensitive troponin I assay and risk of recurrent myocardial infarction and death in patients with suspected acute coronary syndrome. JAMA 2011;305:1210–6.
Mills NL, Lee KK, McAllister DA, Anand A, Gamble D, Shah AS, et al. Implications of lowering threshold of plasma troponin concentration in diagnosis of myocardial infarction: cohort study. BMJ 2012;344:e1533
Apple FS, Collinson PO. Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem 2012;58:54–61.
Apple FS, Ler R, Murakami MM. Determination of 19 cardiac troponin I and T assay 99th percentile values from a common presumably healthy population. Clin Chem 2012;58:1574–81 DOI: https://doi.org/10.1373/clinchem.2012.192716
Korraa, A., Ezzat, M.H., Bastawy, M., Aly, H., El-Mazary, A.A. and Abd El-Aziz, L., 2012. Cardiac troponin I levels and its relation to echocardiographic findings in infants of diabetic mothers. Italian Journal of Pediatrics, 38, pp.1-8. DOI: https://doi.org/10.1186/1824-7288-38-39
Selvanayagam JB, Porto I, Channon K, Petersen SE, Francis JM, Neubauer S, Banning AP. Troponin elevation after percutaneous coronary intervention directly represents the extent of irreversible myocardial injury: insights from cardiovascular magnetic resonance imaging. Circulation. 2005;111:1027– 1032. DOI: https://doi.org/10.1161/01.CIR.0000156328.28485.AD
Giannitsis E, Steen H, Kurz K, Ivandic B, Simon AC, Futterer S, Schild C, Isfort P, Jaffe AS, Katus HA. Cardiac magnetic resonance imaging study for quantification of infarct size comparing directly serial versus single timepoint measurements of cardiac troponin T. J Am Coll Cardiol. 2008;51:307– 314. DOI: https://doi.org/10.1016/j.jacc.2007.09.041
Chia S, Senatore F, Raffel OC, Lee H, Wackers FJ, Jang IK. Utility of cardiac biomarkers in predicting infarct size, left ventricular function, and clinical outcome after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. JACC Cardiovasc Interv. 2008;1:415–423. DOI: https://doi.org/10.1016/j.jcin.2008.04.010
Morrow DA, Cannon CP, Jesse RL, Newby LK, Ravkilde J, Storrow AB, Wu AH, Christenson RH; National Academy of Clinical Biochemistry. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation. 2007;115:e356–e375 DOI: https://doi.org/10.1161/CIRCULATIONAHA.107.182882
Mahmoud KD, Hillege HL, Jaffe AS, Lennon RJ, Holmes DR. Biochemical validation of patient-reported symptom onset time in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. JACC Cardiovasc Interv. 2015;8:778–787. DOI: https://doi.org/10.1016/j.jcin.2014.12.242
Moscucci M, Share D, Kline-Rogers E, O’Donnell M, Maxwell-Eward A, Meengs WL, Clark VL, Kraft P, De Franco AC, Chambers JL, Patel K, McGinnity JG, Eagle KA; the Blue Cross Blue Shield of Michigan Cardiovascular Consortium. The Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) collaborative quality improvement initiative in percutaneous coronary interventions. J Interv Cardiol. 2002;15:381–386. DOI: https://doi.org/10.1111/j.1540-8183.2002.tb01071.x
Kline-Rogers E, Share D, Bondie D, Rogers B, Karavite D, Kanten S, Wren P, Bodurka C, Fisk C, McGinnity J, Wright S, Fox S, Eagle KA, Moscucci M; the Blue Cross Blue Shield of Michigan Cardiovascular Consortium. Development of a multicenter interventional cardiology database: the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) experience. J Interv Cardiol. 2002;15:387–392. DOI: https://doi.org/10.1111/j.1540-8183.2002.tb01072.x
NCDR CathPCI Registry v4.4 Coder’s Data Dictionary. American College of Cardiology Foundation; 2011. Available at: https://www.ncdr.com/Web NCDR/docs/public-data-collection-documents/cathpci_v4_codersdictionary_ 4-4.pdf. Accessed January 31, 2018.
Sharma S, Jackson PG, Makan J. Cardiac troponins. J Clin Pathol 2004;57(10):1025–1026 . DOI: https://doi.org/10.1136/jcp.2003.015420
Peacock WF, Baumann BM, Bruton D, et al. Efficacy of high-sensitivity troponin T in identifying very-low-risk patients with possible acute coronary syndrome. JAMA Cardiol 2018;3(2):104–111 DOI: https://doi.org/10.1001/jamacardio.2017.4625
Westermann D, Neumann JT, Sörensen NA, Blankenberg S. High-sensitivity assays for troponin in patients with cardiac disease. Nat Rev Cardiol 2017;14(8):472–483 DOI: https://doi.org/10.1038/nrcardio.2017.48
Xue Y, Clopton P, Peacock WF, Maisel AS. Serial changes in high-sensitive troponin I predict outcome in patients with decompensated heart failure. Eur J Heart Fail 2011;13(37):C42 DOI: https://doi.org/10.1093/eurjhf/hfq210
Wu A. Analytical issues for clinical use of cardiac troponin. In: Morrow D, ed. Cardiovascular biomarkers: pathophysiology and disease management. Humana Press Inc, 2006:25–38 DOI: https://doi.org/10.1007/978-1-59745-051-5_2
Apple FS, Collinson PO, IFCC Task Force on Clinical Applications of Cardiac Biomarkers. Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem 2012;58:54–61.
Roffi M, Patrono C, Collet J-P, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Hear J 2016;37:267–315.
Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. J Am Coll Cardiol 2012;60:1581–98. 26 Jaffe AS, Babuin L. Defining myocardial infarction. In: Morrow DA, ed. Cardiovascular Biomarkers: Pathophysiology and Disease Management. Totowa, NJ: Humana Press Inc, 2006:39–58.
Aw T, Wee L, Lim F. Should both high-sensitivity cardiac troponins (hs-cTn) and CK-MB be tested for evaluation for acute chest pain in the emergency department (ED). Ann Acad Med 2015;44:S27
Mills .NL, Churchhouse AM, Lee KK, et al. Implementation of a sensitive troponin I assay and risk of recurrent myocardial infarction and death in patients with suspected acute coronary syndrome. JAMA 2011;305:1210–6. DOI: https://doi.org/10.1001/jama.2011.338
Mills NL, Lee KK, McAllister DA, Anand A, Gamble D, Shah AS, et al. Implications of lowering threshold of plasma troponin concentration in diagnosis of myocardial infarction: cohort study. BMJ 2012;344:e1533. DOI: https://doi.org/10.1136/bmj.e1533
Everett BM, Brooks MM, Vlachos HE, Chaitman BR, Frye RL, Bhatt DL, BARI 2D Study Group. Sex differences in cardiac troponin and the risk of death or major cardiovascular events. J Am Coll Cardiol. 2016;68(9):978- 980.
Everett BM, Brooks MM, Vlachos HE, Chaitman BR, Frye RL, Bhatt DL, BARI 2D Study Group. Sex differences in cardiac troponin and the risk of death or major cardiovascular events. J Am Coll Cardiol. 2016;68(9):978- 980. DOI: https://doi.org/10.1016/j.jacc.2016.06.013
Gore MO, Seliger SL, Defilippi CR, Nambi V, Christenson RH, Hashim IA, Hoogeveen RC, et al. Age- and sex-dependent upper reference limits for the high-sensitivity cardiac troponin T assay. J Am Coll Cardiol. 2014;63(14):1441-1448. DOI: https://doi.org/10.1016/j.jacc.2013.12.032
Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267-315. DOI: https://doi.org/10.1093/eurheartj/ehv320
Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD, et al. Fourth universal definition of myocardial infarction (2018). Circulation. 2018;138(20):e618-e651. DOI: https://doi.org/10.1161/CIR.0000000000000617
Apple FS, Collinson PO, Biomarkers ITFoCAoC. Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem. 2012;58(1):54-61. DOI: https://doi.org/10.1373/clinchem.2011.165795
Mueller-Hennessen M, Lindahl B, Giannitsis E, Biener M, Vafaie M, deFilippi CR, Christ M, et al. Diagnostic and prognostic implications using age- and gender-specific cut-offs for high-sensitivity cardiac troponin T - Sub-analysis from the TRAPID-AMI study. Int J Cardiol. 2016;209:26-33. DOI: https://doi.org/10.1016/j.ijcard.2016.01.213
Rubini Gimenez M, Twerenbold R, Boeddinghaus J, Nestelberger T, Puelacher C, Hillinger P, Wildi K, et al. Clinical effect of sex-specific cutoff values of high-sensitivity cardiac troponin T in suspected myocardial infarction. JAMA Cardiol. 2016;1(8):912-920. DOI: https://doi.org/10.1001/jamacardio.2016.2882
McRae A, Graham M, Abedin T, Ji Y, Yang H, Wang D, Southern D, et al. Sex-specific, high-sensitivity cardiac troponin T cut-off concentrations for ruling out acute myocardial infarction with a single measurement. CJEM. 2019;21(1):26-33. DOI: https://doi.org/10.1017/cem.2018.435
Shah AS, Griffiths M, Lee KK, McAllister DA, Hunter AL, Ferry AV, Cruikshank A, et al. High sensitivity cardiac troponin and the under-diagnosis of myocardial infarction in women: prospective cohort study. BMJ. 2015;350:g7873 DOI: https://doi.org/10.1136/bmj.g7873
Tiller NB, Wheatley-Guy CM, Fermoyle CC, Robach P, Ziegler B, Gavet A, Schwartz JC, et al. Sex-specific physiological responses to ultramarathon. Med Sci Sports Exerc. 2022;54(10):1647-1656 DOI: https://doi.org/10.1249/MSS.0000000000002962
Stearns JD, Davila-Roman VG, Barzilai B, Thompson RE, Grogan KL, Thomas B, Hogue CW, Jr. Prognostic value of troponin I levels for predicting adverse cardiovascular outcomes in postmenopausal women undergoing cardiac surgery. Anesth Analg. 2009;108(3):719-726. DOI: https://doi.org/10.1213/ane.0b013e318193fe73
Chaulin AM, Duplyakov DV. Analytical review of modern information on the physiological and pathochemical mechanisms of the release of cardiospecific proteins from muscle tissue, methodology and technologies of their research, interpretation of the results. Laboratory Diagnostics. Eastern Europe. 2022;11(1):78-97. (In Russian). DOI: https://doi.org/10.34883/PI.2022.11.1.018
White HD. Pathobiology of troponin elevations: do elevations occur with myocardial ischemia as well as necrosis? J Am Coll Cardiol. 2011;57(24):2406-2408. DOI: https://doi.org/10.1016/j.jacc.2011.01.029
Chaulin AM. [Main analytical characteristics of laboratory methods for the determination of cardiac troponins: a review from the historical and modern points of view]. Orv Hetil. 2022;163(1):12-20 DOI: https://doi.org/10.1556/650.2022.32296
Neal RC, Ferdinand KC, Ycas J, Miller E. Relationship of ethnic origin, gender, and age to blood creatine kinase levels. Am J Med. 2009;122(1):73-78. DOI: https://doi.org/10.1016/j.amjmed.2008.08.033
Clifford SM, Bunker AM, Jacobsen JR, Roberts WL. Age and gender specific pediatric reference intervals for aldolase, amylase, ceruloplasmin, creatine kinase, pancreatic amylase, prealbumin, and uric acid. Clin Chim Acta. 2011;412(9-10):788-790. DOI: https://doi.org/10.1016/j.cca.2011.01.011
Zaninotto M, Mion MM, Novello E, Delprete E, Moretti M, Plebani M. Creatine-kinase MB mass: age and sexassociated reference limits in two different platforms that use the same method. Clin Chim Acta. 2009;401(1- 2):162-164 DOI: https://doi.org/10.1016/j.cca.2008.12.003
Published
Issue
Section
License
Copyright (c) 2024 Academic International Journal of Medical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
